Patient-derived organoids (PDOs) recapitulate tumor architecture, contain cancer stem cells
and have predictive value supporting personalized medicine. Here we describe a large …

Patient-derived organoids (PDOs) have recently emerged as robust preclinical models;
however, their potential to predict clinical outcomes in patients has remained unclear. We …

Precision oncology presumes an accurate prediction of drug response on the basis of the
molecular profile of tumors. However, the extent to which patient-derived tumor organoids …

Abstract Background Patient derived organoids (PDOs) can be established from colorectal
cancers (CRCs) as in vitro models to interrogate cancer biology and its clinical relevance …

Patient-derived tumor organoids (TOs) are emerging as high-fidelity models to study cancer
biology and develop novel precision medicine therapeutics. However, utilizing TOs for …

Cancer stem cells (CSCs) are hypothesized to actively maintain tumors similarly to how their
normal counterparts replenish differentiated cell types within tissues, making them an …

Patient-derived organoids (PDOs) are widely heralded as a drug-screening platform to
develop new anti-cancer therapies. Here, we use a drug-repurposing library to screen PDOs …

Organoids are in vitro self-assembling, organ-like, three-dimensional cellular structures that
stably retain key characteristics of the respective organs. Organoids can be generated from …

Background The T cell bispecific antibody cibisatamab (CEA-TCB) binds Carcino-Embryonic
Antigen (CEA) on cancer cells and CD3 on T cells, which triggers T cell killing of cancer cell …

Accumulating evidence indicates that patient-derived organoids (PDOs) can predict drug
responses in the clinic, but the ability of PDOs to predict responses to chemoradiation in …